Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | Case report

Nivolumab

Spondylarthritis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Meisels E, et al. Development of Spondyloarthritis Following Treatment with an Immune Checkpoint Inhibitor in a Patient with Metastatic Melanoma: A Case Report. The Journal of Rheumatology 50 (Suppl. 1): 66 abstr. 57, No. 7, et al. Jul 2023. Available from: URL: http://doi.org/10.3899/jrheum.2023-0216 Meisels E, et al. Development of Spondyloarthritis Following Treatment with an Immune Checkpoint Inhibitor in a Patient with Metastatic Melanoma: A Case Report. The Journal of Rheumatology 50 (Suppl. 1): 66 abstr. 57, No. 7, et al. Jul 2023. Available from: URL: http://​doi.​org/​10.​3899/​jrheum.​2023-0216
Metadaten
Titel
Nivolumab
Spondylarthritis: case report
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45956-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Levetiracetam

Case report

Multiple drugs

Case report

Promazine